You are here: Industry Insights > Sun Pharma

News List

Sun Pharma reports Q1 net profit at Rs.1,387 biospectrumasia
August 15, 2019
Sun Pharmaceutical Industries Ltd. reported financials for the first quarter ending June 30th, 2019.
Sun Pharma reports Q1FY20 results expresspharma
August 15, 2019
Sun Pharmaceutical Industries has announced its Q1FY20 results, reporting a surge of 16 per sent in its gross sales which stood at Rs.8,259 crores. The net profit also witnessed a hike of 31 per cent at Rs 1387 crores.
Sun Pharma Announces Licensing Agreement With CSIR-IICT expresspharma
August 15, 2019
Sun Pharmaceuticals has announced that it has entered into a global licensing agreement with the CSIR Indian Institute of Chemical Technology, Hyderabad (CSIR-IICT), for patents related to certain compounds with ...
Sun Pharma Shuts Two Clinical Pharmacology Units in Vadodara expresspharma
August 05, 2019
Drug major Sun Pharma announced that it is discontinuing operations at two clinical pharmacology units in Vadodara (Gujarat) to bring in efficiencies in cost and processes.
Sun Pharma announces regulatory filing of Tildrakizumab in Japan biospectrumasia
August 01, 2019
Filing is a significant milestone in establishing the specialty business in Japan and adds one more potential market for Tildrakizumab globally
Sun Pharma and CMS to commercialise CsA eye drops in China pharmaceutical-technology
July 01, 2019
A subsidiary of Sun Pharmaceutical Industries has signed an agreement with a China Medical System (CMS) subsidiary to develop and commercialise Cyclosporine A 0.09% (CsA) eye drops.
Sun Pharma and CMS enter into a License Agreement for Cyclosporine A and Tildrakizumab in Greater… expressbpd
June 28, 2019
Under the terms of the license agreement, CMS will pay Sun Pharma an initial upfront payment, regulatory and sales milestone payments, and royalties on net sales, the terms of which are confidential
Sun Pharma Announces Data Showing Potential of ILUMYA™ to Improve Psoriatic Arthritis Symptoms americanpharmaceuticalreview
June 20, 2019
Sun Pharmaceutical announced interim results from a Phase 2 study of interleukin-23 (IL-23) inhibitor ILUMYA™ (tildrakizumab-asmn) in patients with active psoriatic arthritis. The interim analysis revealed that over 71 percent of patients treated with ...
Sun Pharma’s ILUMYA improves joint and skin symptoms of Psoriatic Arthritis biospectrumasia
June 16, 2019
Over 71% of Patients Treated with ILUMYA™ Achieved ACR20 Response After 24 Weeks, with Significant Improvement as Early as 8 Weeks
Sun Pharma announces Q4FY19 financial results expressbpd
May 30, 2019
According to the company, the gross sales for Q4 witnessed a hike of 21 per cent, amounting to Rs 8129 crore

Previous page 1 2 3 4 5 6 7 8 9 Next page